HomeQuestion

How does your institution manage node positive bladder cancer in the era of EV + Pembro and how does the approach differ between N1 vs N2-3?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?

How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?

When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?

What are the treatment options for a patient with unfavorable intermediate risk PCa who desires future child bearing?

Will you extrapolate EORTC 1333/PEACE-3 (enzalutamide + Rad223) to any other ARPIs for mCRPC?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.